Substance / Medication

Pralatrexate

Overview

Active Ingredient
pralatrexate
RxNorm CUI
662019

Indications

Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). see Clinical Studies (14) [] This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Labeler: Dr.Reddy's Laboratories Inc.,Updated: 2025-08-31T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
Bhurani Mansi, Admojo Lorenz, Van Der Weyden Carrie et al. · Leuk Lymphoma · 2021
PMID: 33026266Observational
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong Jung Yong, Yoon Dok Hyun, Yoon Sang Eun et al. · Sci Rep · 2019
PMID: 31889144ObservationalFull text (PMC)
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
Visentin Michele, Unal Ersin Selcuk, Zhao Rongbao et al. · Cancer Chemother Pharmacol · 2013
PMID: 23881211ObservationalFull text (PMC)
Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.
Tomita Naoto, Kitazume Koichi, Kitajima Toshiki et al. · J Clin Exp Hematop · 2025
PMID: 40582837Case ReportFull text (PMC)
[Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma].
Sawada Koichi, Sata Hiroshi, Yasumi Masato et al. · Gan To Kagaku Ryoho · 2020
PMID: 32381871Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pralatrexate (substance)
SNOMED CT
428598004
UMLS CUI
C1721300
RxNorm CUI
662019
Labeler
Dr.Reddy's Laboratories Inc.,

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.